journal article·2015-02-27

Formulation and optimization of efavirenz nanosuspensions using the precipitation-ultrasonication technique for solubility enhancement

Sakshi Taneja, Satish Shilpi, Kapil Khatri

Publisher page

Abstract

Efavirenz is a non-nucleoside reverse transcriptase inhibitor, and is classified as BCS Class II API. Its erratic oral absorption and poor bioavailability make it a potential candidate for being formulated as a nanosuspension. The objective of this study was to formulate efavirenz nanosuspensions employing the antisolvent precipitation-ultrasonication method, and to enhance its solubility by reducing particle size to the nanometer range. The effects of different process parameters were studied and optimized with respect to particle size and poly dispersity index (PDI). The optimized formulation was also subjected to lyophilization, to further increase the solubility and stability, and the technology is potentially suited to a range of poorly water-soluble compounds.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Drug Solubulity and Delivery Systems · Protein purification and stability · Analytical Chemistry and Chromatography

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (23)

Show source-provided references
1. Bindu M · Int J Pharm Investig · 2011 · 1 · 2910.4103/2230-973X.76726 ↗
2. Costa MA · Pharmaceutics · 2013 · 5 · 110.3390/pharmaceutics5010001 ↗
3. Dahan A · AAPS J · 2012 · 14 · 24410.1208/s12248-012-9337-6 ↗
4. 10.3797/scipharm.1103-1710.3797/scipharm.1103-17 ↗
5. Eerdenbrugh BV · AAPS Pharm Sci Tech · 2009 · 10 · 4410.1208/s12249-008-9170-5 ↗
6. 10.1007/s11051-008-9357-410.1007/s11051-008-9357-4 ↗
7. Deepali G · J Young Pharm · 2010 · 2 · 41710.4103/0975-1483.71628 ↗
8. Kallings LO · J Intern Med · 2008 · 263 · 21810.1111/j.1365-2796.2007.01910.x ↗
9. 10.1016/j.addr.2007.05.00310.1016/j.addr.2007.05.003 ↗
10. 10.2174/15672010978704830210.2174/156720109787048302 ↗
11. Patel GV · Drug Deliv Ind Pharm · 2013 · 40 · 8010.3109/03639045.2012.746362 ↗
12. 10.4103/2231-4040.7979910.4103/2231-4040.79799 ↗
13. 10.1016/j.supflu.2005.09.00510.1016/j.supflu.2005.09.005 ↗
14. 10.1111/j.2042-7158.2010.01022.x10.1111/j.2042-7158.2010.01022.x ↗
15. Prasanna L · Int J Pharm Pharm Sci · 2010 · 2 · 35
16. 10.1016/S0896-8446(98)00129-610.1016/S0896-8446(98)00129-6 ↗
17. Shafer RW · Biomed Pharmacother · 1999 · 532 · 7310.1016/S0753-3322(99)80063-8 ↗
18. 10.1208/s12249-008-9170-510.1208/s12249-008-9170-5 ↗
19. 10.1016/j.ijpharm.2008.07.02310.1016/j.ijpharm.2008.07.023 ↗
20. Xia D · Eur J Pharm Sci · 2010 · 40 · 32510.1016/j.ejps.2010.04.006 ↗
21. 10.1002/pro.75510.1002/pro.755 ↗
22. Zhang Y · Artif Cells Nanomed Biotechnol · 2014 · 6 · 1
23. 10.1021/ie070498e10.1021/ie070498e ↗